We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$18.6M
Cap. Flow
+$5.56M
Cap. Flow %
1.53%
Top 10 Hldgs %
25.94%
Holding
173
New
49
Increased
12
Reduced
23
Closed
40

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$20.1M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.18M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.64M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.41M
5
QDEL icon
QuidelOrtho
QDEL
+$5.15M

Top Sells

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$7.59M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.09M
3
CDNA icon
CareDx
CDNA
+$5.7M
4
HAE icon
Haemonetics
HAE
+$5.22M
5
LITS
Lite Strategy Inc
LITS
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 7.92%
3 Technology 1.93%
4 Industrials 1.24%
5 Communication Services 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
151
ProQR Therapeutics
PRQR
$268M
– –
-125,000
Closed -$1.05M
ALP
152
Alpha Compute
ALP
$4.28M
– –
-3,750
Closed -$1.52M
SCYX icon
153
SCYNEXIS
SCYX
$51.6M
– –
-8,750
Closed -$371K
SNDX icon
154
Syndax Pharmaceuticals
SNDX
$1.76B
– –
-108,000
Closed -$2.06M
VREX icon
155
Varex Imaging
VREX
$516M
– –
-158,000
Closed -$4.46M
XENE icon
156
Xenon Pharmaceuticals
XENE
$6.24B
– –
-216,000
Closed -$3.3M
XFOR icon
157
X4 Pharmaceuticals
XFOR
$393M
– –
-26,820
Closed -$4.26M
CMRX
158
DELISTED
Chimerix, Inc.
CMRX
– –
-281,790
Closed -$1.74M
VINC
159
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-5,381
Closed -$1.74M
PSTX
160
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-32,238
Closed -$235K
KA
161
DELISTED
Kineta, Inc. Common Stock
KA
– –
-28,000
Closed -$2.02M
CERE
162
PUT
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-20,700
Closed -$611K
TCON
163
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
-39,267
Closed -$3.04M
GRTX
164
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-300,605
Closed -$2.44M
VRPX
165
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
– –
-1,087
Closed -$1.3M
ARYE
166
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
– –
-100,000
Closed -$1M
ONCR
167
DELISTED
Oncorus, Inc.
ONCR
– –
-192,054
Closed -$1.79M
TCRR
168
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-59,150
Closed -$503K
ELOX
169
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
– –
-27,950
Closed -$1.82M
PHAS
170
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-775,000
Closed -$2.41M
ALNA
171
DELISTED
Allena Pharmaceuticals
ALNA
– –
-1,067,886
Closed -$963K
HCAQ
172
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
– –
-200,000
Closed -$1.98M
ADMS
173
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-625,469
Closed -$3.07M
3 4 5 6
7

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Altium Capital Management held 173 positions worth $363M, down 4.9% from $381M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Altium Capital Management's Q4 2021 filing shows 49 new, 12 increased, 23 reduced and 40 closed positions. Its largest new stake was Esperion Therapeutics: 2,515,785 shares worth $12.6M. The largest sale was Aldeyra Therapeutics, an estimated $7.59M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Technology.

  • Altium Capital Management's largest Q4 2021 buy was Esperion Therapeutics: 2,515,785 shares worth $12.6M.
  • Altium Capital Management added most to Bicycle Therapeutics in Q4 2021, an estimated $4.41M increase.
  • Altium Capital Management's biggest Q4 2021 reduction was Cerus, cutting an estimated $4.27M.
  • Altium Capital Management fully exited Aldeyra Therapeutics in Q4 2021, selling an estimated $7.59M.
  • Altium Capital Management's ten largest holdings make up 26% of its $363M portfolio in Q4 2021.
  • Altium Capital Management opened 49 new positions and closed 40 in Q4 2021.
  • Altium Capital Management's portfolio value fell 4.9% quarter-over-quarter to $363M.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.